

---

**Industry:** Biotech

**Management:**

- Executive Leadership: Dr. Yaw Ansong Jnr, Timothy Adamson
  
- Scientific Advisory Board: Kagya Amoako, Phd; Saion Sinha, PhD; Matt Rinehart, Phd

**Finance:**

- Current Investors / Financing to Date: \$31K in grants
  
- Amount of Financing Sought: 500K

**Legal:** Murtha Cullina

---

**Executive Summary:**

Current confirmatory blood diagnostic tests for sickle cell disease is expensive, time-consuming and require skilled personnel. The same is true for other red cell infections such as Malaria and blood diseases such as blood cancers. The idea is provide a quick and affordable AI Backed diagnostic platform.

---

**Company History:**

Yaw is a medical doctor from Ghana and a carrier of the Sickle Cell gene. During his practice as a doctor, he saw the devastating effect sickle cell had on his personal relationships as well as his patients. He saw troubled families struggling to afford a diagnosis. This piqued his interest in finding an affordable and reliable diagnostic solution for sickle cell. During graduate school, I met Tim and we discussed how AI can be applied to diagnosis. After settling on sickle cell KOVA was born.

---

**Market Opportunity / Unmet Need:**

There are currently over 200 Million people with the sickle cell gene. The global hemoglobinopathies market is worth close to \$5.3Bn. Current confirmatory diagnostic tools require skilled personnel, which are expensive and difficult to use. The global malaria diagnostics market is poised to reach \$1 Bn.

---

**Products/Services - Launched & Pipeline:**

Based on Quantitative Phase Imaging (Wide Field Digital Interferometry). Primary technology licensed from Duke. Provisional patent for other property improvements filed.

---

**Commercial / Technical Milestones:**

Currently building version 2 of our product. We are derisking our product by building our own 3d phase imaging unit; after which we will automate our device with the deep learning algorithm we build.

---

**Competition:**

There is currently not a single test available to diagnose and monitor health of sickle cell patients. Our test not only provides this but also provides it in a faster, more affordable and easier to use way.

---

**Financial Projections (Unaudited):** We project \$150M in yearly global revenues within 3 years of launch

---

**Please indicate primary purpose of Presentation:** Investment